Apellis (NASDAQ: APLS) CMO sells 2,797 shares for tax withholding

Rhea-AI Filing Summary

Apellis Pharmaceuticals Chief Medical Officer Caroline Baumal reported a routine insider transaction involving company common stock. On January 22, 2026, she sold 2,797 shares of Apellis common stock at a price of $21.7654 per share. According to the footnote, these shares were sold specifically to cover tax withholding obligations arising from restricted stock units that were released on January 21, 2026.

After this sale, Baumal beneficially owned 86,527 Apellis shares, all held directly. The filing characterizes this as a tax-related sale rather than a discretionary open-market reduction in her overall ownership.

Insider Trade Summary

Net Seller: 2,797 shares ($60,878)

Net Sell 1 txn

Insider Baumal Caroline

Role Chief Medical Officer

Sold 2,797 shs ($61K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,797	$21.7654	$61K

Holdings After Transaction: Common Stock — 86,527 shares (Direct)

Footnotes (1)

1. [object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Baumal Caroline

(Last) (First) (Middle)

C/O APELLIS PHARMACEUTICALS, INC.

100 FIFTH AVENUE, 3RD FLOOR

(Street)

WALTHAM MA 02451

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Apellis Pharmaceuticals, Inc. [ APLS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/22/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/22/2026		S(1)		2,797	D	$21.7654	86,527	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This represents shares sold to cover tax withholding on the Restricted Stock Units released on January 21, 2026.

	/s/ David Watson, attorney-in-fact for Caroline Baumal	01/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Apellis (APLS) report for Caroline Baumal?

Apellis reported that Chief Medical Officer Caroline Baumal sold 2,797 shares of the companys common stock on January 22, 2026.

At what price were the Apellis (APLS) shares sold in this Form 4?

The 2,797 Apellis common shares reported in the Form 4 were sold at an average price of $21.7654 per share.

Why did Apellis CMO Caroline Baumal sell 2,797 shares?

The filing states that the 2,797 shares were sold to cover tax withholding on restricted stock units that were released on January 21, 2026.

How many Apellis (APLS) shares does Caroline Baumal own after this transaction?

Following the reported sale, Caroline Baumal beneficially owns 86,527 shares of Apellis common stock, held directly.

What is Caroline Baumals role at Apellis Pharmaceuticals (APLS)?

In this filing, Caroline Baumal is identified as an officer of Apellis Pharmaceuticals, serving as Chief Medical Officer.

Does the Form 4 indicate any derivative securities for Apellis (APLS)?

The excerpted Form 4 shows activity only in non-derivative common stock, with no derivative securities listed in the transaction table.